Immortality of cancers
A consequence of inherent karyotypic variations and selections for autonomy

Peter Duesberg* and Amanda McCormack

Department of Molecular and Cell Biology; Donner Laboratory; University of California at Berkeley; Berkeley, CA USA

Keywords: clonal and flexible cancer karyotypes, karyotypic linkage of immortality and tumorigenicity, aneuploidy proximate carcinogen, growth advantages of aneuploidy, long preneoplastic latency, low probability of speciation, selection for cancer-specific autonomy, Muller’s ratchet, sub-speciation via karyotypic drift, karyotypes of immortal clones of telomerase-deficient mice

Immortality is a common characteristic of cancers, but its origin and purpose are still unclear. Here we advance a karyotypic theory of immortality based on the theory that carcinogenesis is a form of speciation. Accordingly, cancers are generated from normal cells by random karyotypic rearrangements and selection for cancer-specific reproductive autonomy. Since such rearrangements unbalance long-established mitosis genes, cancer karyotypes vary spontaneously but are stabilized perpetually by clonal selections for autonomy. To test this theory we have analyzed neoplastic clones, presumably immortalized by transfection with overexpressed telomerase or with SV40 tumor virus, for the predicted clonal yet flexible karyotypes. The following results were obtained: (1) All immortal tumorigenic lines from cells transfected with overexpressed telomerase had clonal and flexible karyotypes; (2) Searching for the origin of such karyotypes, we found spontaneously increasing, random aneuploidy in human fibroblasts early after transfection with overexpressed telomerase; (3) Late after transfection, new immortal tumorigenic clones with new clonal and flexible karyotypes were found; (4) Testing immortality of one clone during 848 unselected generations showed the chromosome number was stable, but the copy numbers of 36% of chromosomes drifted ± 1; (5) Independent immortal tumorigenic clones with individual, flexible karyotypes arose after individual latencies; (6) Immortal tumorigenic clones with new flexible karyotypes also arose late from cells of a telomerase-deficient mouse rendered aneuploid by SV40 virus. Because immortality and tumorigenicity: (1) correlated exactly with individual clonal but flexible karyotypes; (2) originated simultaneously with such karyotypes; and (3) arose in the absence of telomerase, we conclude that clonal and flexible karyotypes generate the immortality of cancers.

The currently prevailing immortality theory postulates that cells are immortalized by activation of telomerase. Since this enzyme is developmentally switched off in somatic cells, cancers are said to derive immortality from activation of telomerase. According to this theory, “Cells that have stabilized their telomeres through the actions of telomerase or the ALT mechanism proliferate indefinitely and are therefore said to be immortalized. Cell immortalization is a step that appears to govern the development of all human cancers.”

But, even telomerase genes that are artificially overexpressed by a cytomegalovirus- and a retrovirus-derived promoter are not sufficient, and not even necessary to immortalize cells for the following reasons: mass cultures of “polyclonally” transfected cells are karyotypically unstable and thus not immortal for many, up to over 100 unstable, generations before they become immortal and clonal. Only < 1 in 10^5 cells of mass cultures transfected with artificially overexpressed telomerase genes (linked also to drug-resistance indicator genes) become clones of immortal cells. Studying carcinogenesis in...
reproductive autonomy. Since such rearrangements unbalance long-established mitosis genes, cancer karyotypes vary spontaneously but are stabilized perpetually by clonal selections for autonomy. Immortality of cancers is thus a direct consequence of a dynamic equilibrium between spontaneous karyotypic variation and selection for reproductive autonomy—as it is in principle also for sexual species, although at a much lower rate.50-55 This dynamic equilibrium between variation and selection for autonomy also explains the constitutive heterogeneity of cancer karyotypes.56-58 The theory thus predicts that autonomous clonal but flexible karyotypes generate immortality.

To test this theory, we asked whether immortality of human cell lines, currently attributed to transfection with overexpressed telomerase, correlates with clonal flexible karyotypes, and whether immortality originates simultaneously with such karyotypes. Further we asked, whether in the absence of telomerase, SV40 tumor virus induces immortal neoplastic clones with flexible karyotypes in cells of a telomerase-deficient mouse.

Results

Immortal tumorigenic clones derived from human cells transfected with overexpressed telomerase have clonal flexible karyotypes. As a first test of the theory that karyotypic flexibility immortalizes we asked, whether flexible clonal karyotypes are present in three known immortal tumorigenic cell lines named HA1, HA1-2 and BJ.29 These lines arose from mass cultures of primary human kidney (HA1 and HA1-2) and skin cells (BJ), “approximately 60 population doublings” after transfection with artificially overexpressed telomerase and two artificially overexpressed oncogenes.29

Because of these long latent periods we have questioned in the past whether the transfected genes were sufficient for tumorigenicity and immortalization. In a first effort to find an alternative explanation, we looked for cancer-specific aneuploidy, and found that all three of these cell lines were highly aneuploid.59,60 An initial karyotype of HA1, prepared here as described in “Materials and Methods,” confirmed our earlier findings of aneuploidy (Fig. 1).

In view of this and our new karyotypic immortality theory, we ask now whether the three cell lines contain the clonal and flexible karyotypes predicted by this theory. For this purpose we used 3-dimensional arrays of 20 karyotypes—a technique, which

Figure 1. Karyotype of the immortal tumorigenic HA1 cell line, which originated late after transfection of human kidney cells with overexpressed telomerase. The chromosomes were prepared from metaphases and labeled by hybridization with chromosome-specific colors as described in “Materials and Methods.”
Figure 2. For figure legend, see page 786.
we had recently developed to detect clonality within the karyotypic heterogeneity of cancers.11,45,64 Such karyotype arrays list chromosome numbers on the x-axis, chromosome copy numbers on the y-axis and the number of metaphases arrayed on the z-axis.

The karyotype arrays of HA1, HA1–2 and BJ, shown in Figure 2 and Table 1, clearly indicate that all three cell lines were clonal: the chromosome numbers of HA1 were 82 ± 1, those of HA1–2 were 47 ± 4, and those of BJ were 82 ± 5, and thus highly clonal. Moreover, the copy numbers of the individual chromosomes of HA1 were 85 to 100% clonal, those of HA1–2 were 85 to 90% clonal, and those of BJ were 75 to 100% clonal. As a result of this high clonality, the copy numbers of most chromosomes of the three lines formed parallel lines in the arrays shown Figure 2. By contrast, a minority of chromosome numbers differed from the clonal values within narrow margins of ± 1 and thus stood out above or below the patterns formed by the parallel lines. The relative clonality and non-clonality can thus be seen in each array at a glance. In sum, all three cell lines contained the clonal and flexible karyotypes predicted by our theory.

Further studies from other researchers including us have confirmed that other immortal tumorigenic lines derived from mass cultures of human cells transfected with artificially overexpressed telomerase, and various oncogenes also contain clonal and flexible karyotypes and also had evolved only late after transfection with overexpressed telomerase and additional oncogenes.42,45,63,62

Conclusions. (1) Based on exact correlations between tumorigenicity and immortality and clonal but flexible karyotypes in all neoplastic clones derived from cells transfected with overexpressed telomerase, we conclude that such karyotypes are necessary, perhaps even sufficient, for immortality.

(2) Based on the clonality of the three tumorigenic and immortal clones and the long pre-neoplastic and pre-immortal latencies of 60 generations from transfection with overexpressed genes, we conclude that tumorigenesis and immortalization are extremely rare and possibly simultaneous clonal events. It follows that overexpressed telomerase and overexpressed oncogenes are not sufficient for immortalization and transformation.

In the following we ask how overexpressed telomerase induces immortal tumorigenic clones, and whether it plays a lasting role in their immortality.

How does overexpressed telomerase induce immortal tumorigenic clones? The speciation theory predicts that carcinogenesis is initiated by random aneuploidy.10–13,45 (Introduction). According to this theory, biological carcinogens like oncogenic viruses and artificially overexpressed cellular genes or non-biological chemical and physical carcinogens, or spontaneous events induce this random aneuploidy.11,45,47,48,61–68 Since aneuploidy unbalances long-established mitosis genes, it self-catalyzes progressions of aneuploidy toward two ends: (1) lethal karyotypes that perish; and (2) new autonomous cancer karyotypes that are stabilized by clonal selection for cancer-specific reproductive autonomy.11,45 (Introduction). Aneuploidy would thus be the proximal carcinogen. Because the probability of generating a new autonomous cancer or other species by random karyotypic rearrangements is very low, the latent periods from initiating aneuploidy to the origin of a new immortal species are very long and the resulting species are clonal, just as it was with the three cell lines described above.

To test the predicted role of random aneuploidy in the generation of an immortal neoplastic clone, we karyotyped human skin fibroblasts that had been immortalized by transfection with overexpressed telomerase by Mondello et al. in Pavia, Italy.32,40 Mondello et al. have studied the time course of immortalization of skin fibroblasts from a centenarian woman from transfection with overexpressed telomerase to over 1,000 generations or population doublings (PD) in vitro.32,40 We were particularly interested in this system, because Mondello et al. had already observed aneuploidy before and after immortalization.32,40

Transfection with overexpressed telomerase induces random aneuploidy prior to immortalization. In agreement with Mondello et

---

**Figure 2** (See previous page). Three-dimensional arrays of 20 karyotypes of the immortal tumorigenic human cell lines HA1 and HA1–2 and BJ based on the cytogenetic data listed in Table 1. HA1 and HA1–2 lines originated late from human kidney cells (Fig. 1), and BJ from human skin cells about 60 generations after transfection of mass cultures with artificially overexpressed telomerase and two overexpressed oncogenes (text). The karyotype arrays are three-dimensional tables, which show the chromosome numbers of 20 karyotypes on the x-axis, the copy numbers of each chromosome on the y-axis and the number of metaphases arrayed on the z-axis. By forming parallel lines, the chromosome copy numbers of 20 karyotypes indicate that the three lines are highly clonal. A minority of non-clonal copy numbers differing from the clonal values in narrow margins of ± 1, stands out above or below these lines (Table 1). This indicates that all three lines have clonal but flexible karyotypes.
we found that after transfection with overexpressed telomerase, the skin cells from a centenarian woman, hence cen3tel, evolved as follows: 37 generations after transfection, at PD37, the cells had a typical fibroblastic, fusiform phenotype (Fig. 3A).

Sixty-three generations later, at PD100, the cen3tel cells still had a basic fibroblastic phenotype. However, during that time, the cells had become less fusiform, had acquired a 2–3-fold higher growth rate and grew to a higher density per culture dish than their PD37 precursors (compare Fig. 3A and B).

The karyotypic analyses of the cen3tel culture at PD37 and PD100 show, in Tables 2 and 3 and Figure 4, that the culture was 60% aneuploid at 37 generations, and was 100% aneuploid at 100 generations after transfection with overexpressed telomerase. Further, while the chromosome copy numbers of aneuploid cells at PD37 were near-diploid, the chromosome copy numbers at PD100 ranged from 1 to 4 and beyond. Thus cen3tel at PD100 differed from PD37 not only in the percentage, but also in the degree of aneuploidy.

Moreover, some aneusomies had reached low degrees of clonality during the progression of aneuploidy from PD37 to PD100. For example, 12 new marker chromosomes of PD100 were shared subclonally by 2–9 of 20 karyotypes, and one new monosomy 2 was shared by five karyotypes (Table 3). At the same time, 15 of 20 cen3tel cells at PD37 had retained a trisomy 7 that was subclonal in the original cen3 biopsy (Table 2 and Fig. 4A). This trisomy 7 was still present in 8 of 20 cen3tel cells at PD100 and in 3 of 20 PD100-cells in the form of a hexasomy 7 (Fig. 4B). Such subclonalities indicate that some randomly generated aneuploidies provide growth advantages.

The spontaneous increases in the percentages and the degrees of aneuploidies, and the evolution of subclonal aneuploidies of the cen3tel culture from PD37 to PD100 thus support the prediction of the speciation theory that aneuploidy progresses automatically based on newly generated growth advantages.

These results also confirm and extend earlier studies of Heng et al. showing that aneuploidies confer growth advantages to somatic cells from humans with genetic instability, and studies of Berman and Pavelka et al. showing that certain aneuploidies confer growth advantages to various strains of yeast. It seems probable, therefore, that such aneuploidy-specific growth advantages might also explain the pre-neoplastic human hyperplasias detected in vivo ever since Papanicolaou.

Conclusions. (1) Overexpressed telomerase is not sufficient for immortalization, because the transfected cells have highly unstable, aneuploid karyotypes.
(2) Transfection of human cells with overexpressed telomerase induces random aneuploidies, which offer growth advantages. As a result of these advantages, the aneuploidies progress spontaneously and even form subclonal subsets. These aneuploidy-generated growth advantages thus explain the 2–3-fold increases in the growth rates of cen3tel cells following transfection with overexpressed telomerase.

New tumorigenic clone evolves late from randomly aneuploid cells. During the 66 cell generations from PD100 to PD166, the cen3tel culture acquired the neoplastic abilities to grow in agar gels and to form tumors in immunodeficient athymic mice. At
To determine whether this cancer-specific phenotypic transformation coincided with the evolution of a new clonal and flexible cancer karyotype, we prepared an array of 20 cen3tel PD166 karyotypes, which is shown in Figure 5A and Table 4. It can be seen in Table 4 that the chromosome numbers of the tumorigenic cen3tel PD166 clone were 76 ± 3, and thus were highly clonal. The table also shows that the 76 clonal chromosomes included 14 new PD166-specific marker chromosomes. Further the array shows that the copy numbers of most chromosomes of the 20 karyotypes were clonal, forming parallel lines, which are characteristic of clonality (see above “Results,” “Immortal tumorigenic clones…”). At the same time a minority of chromosomes were non-clonal, forming non-parallel points within narrow ± 1 margins of variation above and below these parallel lines. The non-clonal copy numbers were thus near-clonal. The percentages of clonal vs. near-clonal chromosome copy numbers ranged from 60 to 100% (Table 4).

Given the rough chronological time points available, we estimate that the stem cell of cen3tel PD166 originated at or before PD146 as follows. Since we maintained cultures of at least 1 million cells, and since it takes about 20 cell generations to multiply one cell to 1 million (10⁶ = 2²⁰), we deduce that the stem cell of PD166 must have arisen at PD146, at least 20 generations before PD166. In the following 20 generations it would have supplanted all non-clonal aneuploid precursors by the new tumorigenic PD166 cells (see also “Discussion” and Fig. 11).

Conclusions. (1) Since neither tumorigenicity, nor clonal and flexible karyotypes, nor non-fibroblastic, polymorphic cell phenotypes were observed in the preneoplastic cen3tel mass culture before PD166, it is hard to escape the conclusion that the new clonal and flexible PD166 karyotype generated the new tumorigenic cen3tel PD166 clone. The recent identification of a new, cen3tel PD166-specific transcriptome by Ostano et al. lends independent support to this conclusion. Using a “heatmap” they showed that none of about 15 (except perhaps 1) cen3tel PD166-specific transcripts were shared with the preneoplastic cen3tel precursors at PD37 and PD97.75 It follows that the new PD166-transcriptome generates the new phenotypes of the cen3tel PD166 clone.

At the same time the cellular phenotype of the cen3tel cells changed completely from fibroblastic spindle-shaped to cubic-polymorphic, which is characteristic of cancer cells (Fig. 3A–C). Moreover the cen3tel cells at PD166 grew 3-dimensionally, which is also characteristic of cancer cells.74
Table 2. Karyotypes of 20 cen3tel cells 37 generations after transfection with overexpressed telomerase

| Metaphases | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
|------------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|
| Chromosome nos. | 47 | 47 | 47 | 47 | 47 | 47 | 47 | 47 | 47 | 44 | 45 | 44 | 44 | 44 | 44 | 46 | 46 | 45 | 27 | 65 |
| Chromosomes near-diploid, native and aneuploid karyotypes | | | | | | | | | | | | | | | | | | | | | |
| 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 |
| 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 |
| 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 3 | 2 | 2 | 2 | 2 |
| 4 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 |
| 5 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 3 |
| 6 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 4 |
| 7 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 5 |
| 8 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 1 |
| 9 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 1 | 2 |
| 10 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 0 | 4 |
| 11 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 |
| 12 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 |
| 13 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 0 | 2 |
| 14 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 3 |
| 15 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 |
| 16 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 1 |
| 17 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 0 | 4 |
| 18 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 |
| 19 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 4 |
| 20 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 2 |
| 21 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 3 |
| 22 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 4 |
| X | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Y | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| t(6;10) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |

(2) The speciation theory also predicts the clonal heterogeneity of the neoplastic cen3tel PD166 clone, based on the underlying karyotypic flexibility of cancer karyotypes (Introduction).

(3) The random, preneoplastic aneuploidies of PD37 and PD100 followed by the new clonal, neoplastic karyotype of PD166 confirm the prediction of the speciation theory that aneuploidy is the proximate carcinogen.

In the following we ask whether the new tumorigenic cen3tel PD166 clone is indeed immortal, and, if so, whether it had acquired immortality together with tumorigenicity.

During 848 unselected generations the clonal chromosome number of cen3tel PD166 is stable, but the copy numbers of 36% of chromosomes drift ± 1. To determine whether the new, tumorigenic cen3tel PD166 clone is immortal in terms of the Hayflick definition, we compared the karyotypes of cen3tel PD166 during 848 unselected generations from PD166, when it was first identified, to its late descendants at PD617 and at PD1014.

These comparisons indicate that the chromosome numbers of cen3tel PD166 were 76 ± 3 at PD166, 72 ± 4 at PD617 and 73 ± 1 at PD1014 and thus were highly clonal and stable over 848 generations (Table 4). The copy numbers of 21 of 33 (64%) PD166 chromosomes were clonally conserved over 848 generations, while 12 of 33 (36%) chromosome numbers drifted within narrow margins of ± 1 (Table 4 and Fig. 5A–C). In addition to this quantitative drift of chromosome copy numbers, cen3tel at PD617 also differed from its precursor PD166 in four new generation-specific clonal markers, and cen3tel PD1014 differed in 10 generation-specific clonal markers (Table 4).

In Figure 6 we show the karyotypic consequences of 848 generations of unselected drift on two randomly selected karyotypes of PD166 and of PD1014 side-by-side. It can be seen that the two karyotypes differed from each other in generation-specific and cell-specific (non-clonal) copy numbers (Table 4) and marker chromosomes (Table 4, also marked in Fig. 6), which could only be distinguished as such with the statistics of the karyotype arrays.

But, despite such variations, the basic karyotype of PD166 was stably clonal and flexible over 848 cell generations. In agreement with the stability of this karyotype, the new transformation-specific phenotype of PD166 was also stable during 848 generations (Fig. 3C and D).

Conclusions. Based on its karyotypic and phenotypic stability over 848 generations, we conclude that cen3tel PD166 is
immortal within clonal margins of variation. Indeed, the evidence for 848 generations of clonal stability and flexibility obtained here far exceeds the operational Hayflick threshold of immortality of 50 generations. This result confirms and extends the theory that the immortality of cancers is karyotypic.

Next, we asked whether tumorigenicity and immortality are also karyotypically united in independent tumorigenic clones, derived from the same primary cen3tel culture from which cen3tel PD166 was obtained.

An independent immortal and tumorigenic clone arises from preneoplastic cen3tel cells after an individual latency. In the following we test the prediction of the speciation theory that tumorigenicity and immortality are karyotypically linked in all neoplastic clones. By contrast, the telomerase theory predicts immortalization to be an independent genetic event and thus not inevitably linked to tumorigenesis.\textsuperscript{5,27}

To distinguish between these alternatives, we studied an independent tumorigenic clone that arose from an aliquot of the same preneoplastic cen3tel cells from which cen3tel PD166 originated. The aliquot was termed cen3telS2 and was maintained and tested for tumorigenicity and immortality exactly like the parental cen3tel culture.

About 84 cell generations after transfection, at PD84, the independently growing cen3telS2 mass culture had become tumorigenic. The individual karyotype of cen3telS2 PD84 indicated that the new clone was indeed independent of cen3tel PD166 (Fig. 7A).
### Table 3. Karyotypes of 20 cent tel cells 100 generations after transfection with overexpressed telomerase

| Metaphase | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
|-----------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|
| Chromosome no. | 47 | 47 | 48 | 49 | 49 | 49 | 90 | 81 | 87 | 88 | 85 | 45 | 46 | 67 | 63 | 52 | 70 | 64 | 66 | 83 |
| Chromosome copy numbers | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 |
| | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 2 | 3 | 2 | 2 | 2 | 2 | 4 | 0 | 2 | 2 | 3 | 3 |
| | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 7 | 4 | 4 | 3 | 3 | 2 | 2 | 3 | 2 | 2 | 3 | 7 | 4 | 4 |
| | 4 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 3 | 4 | 4 | 1 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 3 |
| | 5 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 4 | 3 | 4 | 2 | 2 | 3 | 4 | 2 | 3 | 3 | 4 | 3 |
| | 6 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 2 | 3 |
| | 7 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 6 | 6 | 6 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| | 8 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 4 | 4 | 2 | 2 | 4 | 2 | 4 | 3 | 2 | 3 | 4 | 3 |
| | 9 | 2 | 1 | 2 | 2 | 2 | 1 | 4 | 3 | 4 | 4 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 |
| | 10 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 4 | 3 | 2 | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 3 |
| | 11 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 4 | 2 | 3 | 4 | 1 | 2 | 2 | 2 | 0 | 2 | 2 | 1 |
| | 12 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 4 | 4 | 2 | 2 | 3 | 3 | 2 | 4 | 3 | 4 | 4 |
| | 13 | 2 | 1 | 1 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 1 |
| | 14 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 3 | 2 | 3 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 3 | 2 |
| | 15 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 2 | 3 | 1 | 3 | 2 | 3 | 3 | 1 | 2 | 3 | 3 |
| | 16 | 2 | 1 | 2 | 2 | 2 | 2 | 4 | 2 | 4 | 4 | 4 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 4 |
| | 17 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 3 | 4 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 2 | 1 | 3 | 2 |
| | 18 | 1 | 2 | 2 | 2 | 2 | 2 | 5 | 3 | 4 | 3 | 3 | 2 | 2 | 4 | 3 | 2 | 4 | 3 | 2 |
| | 19 | 2 | 2 | 2 | 2 | 2 | 2 | 5 | 4 | 4 | 4 | 4 | 2 | 2 | 4 | 3 | 4 | 2 | 2 | 2 |
| | 20 | 2 | 2 | 2 | 2 | 2 | 2 | 8 | 4 | 4 | 4 | 4 | 1 | 2 | 4 | 4 | 3 | 4 | 1 | 1 |
| | 21 | 4 | 3 | 3 | 2 | 3 | 3 | 3 | 4 | 3 | 4 | 4 | 1 | 3 | 3 | 3 | 2 | 2 | 1 | 2 |
| | 22 | 2 | 2 | 2 | 2 | 2 | 2 | 5 | 4 | 4 | 3 | 3 | 1 | 2 | 4 | 3 | 4 | 3 | 1 | 3 |
| X | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 1 | 3 | 4 | 4 |
| Y | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| der(14q;2) | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| der(17) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 1 | 0 | 2 | 0 | 1 | 2 | 0 | 2 |
| der(14p;2) | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| der(11:21) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 0 | 1 | 0 | 1 |
| der(21) | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| der(10) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 2 |
| der(11) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 0 |
| der(2;X) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| der(2;6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| der(21;2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| der(8;14;2) | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| der(5;10) | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |

### Non-clonal Markers

| der(2;21) | 1 | 1 |
| der(9;11) | 1 |
| der(21;1) | 1 |
| der(7) | 1 |
| der(22;6) | 1 |
| der(18;19) | 1 |
| der(5;22) | 1 |
To determine whether the new tumorigenic cen3telS2 culture had a new clonal and flexible karyotype, an array of 20 individual karyotypes was prepared (Table 5 and Fig. 8). This array shows that PD84 has a highly clonal chromosome number of 46 ± 1, which included three clonal S2-specific marker chromosomes. The new karyotype was thus pseudo-diploid. The array also shows that the chromosome copy numbers of the cen3telS2 PD84 culture were 75–90% clonal, except for three non-clonal marker chromosomes (Fig. 8A and Table 5). The presence of some non-clonal chromosomes is, of course, expected from the inherent flexibility of neoplastic karyotypes. Thus, cen3telS2 PD84 is a new clone with an individual, clonal and flexible karyotype that independently originated from the preneoplastic cen3tel mass culture described above.

In agreement with the karyotypic individuality of cen3telS2 PD84, the clone differed from cen3tel PD166 in an individual growth rate, which was about two times lower than that of the cen3tel PD166. Moreover, the latent period from the time of transfection of the primary cen3-skin biopsy was much shorter, namely 84 cell generations, compared with the 166 cell generations of the cen3tel PD166 clone.

We infer from available data that the S2 PD84 clone is immortal in terms of the Hayflick definition as follows. In our studies we had passaged the clone for 25 cell generations. In addition, Mondello et al. have tested its stability by demonstrating that the clone is tumorigenic in athymic mice (Mondello, personal communication). Considering that the PD84 stem cell has survived about 30 cell generations to form an experimental tumor of about 1 ml, or 10⁹ cells,⁵,⁷⁴ and that the same PD84 clone has also survived 25 generations in our cultures, the PD84 clone has passed the 50 generation-threshold for immortality by the Hayflick limit. The clone is thus probably immortal, much like the PD166 clone derived from the same preneoplastic cen3tel precursor cells.

Conclusions. (1) The origins of two tumorigenic clones, with different individual clonal karyotypes and phenotypes, and different individual latent periods from the same aneuploid non-neoplastic cen3tel mass culture confirm the prediction of the speciation theory that immortality and tumorigenicity are intrinsic elements of clonal and flexible cancer-specific karyotypes. By contrast, the probability that a genetically independent, 5,76 but non-essential immortalization event (Introduction and Discussion) would coincide with tumorigenicity by chance is only one in a million, because the rates of mutations in cancer cells are only 10⁻⁶.⁷⁷⁻⁷⁹ Compare this to the ubiquity of immortality in cancer. One might argue, however, that cen3tel cells were already immortalized by transfection with overexpressed telomerase. But we have shown in Figure 4 that such cells are karyotypically highly unstable and thus not immortal in themselves.

(2) The origins of two karyotypically unrelated neoplastic clones from the same population of aneuploid cells supports the prediction of the speciation theory that cancers arise stochastically by independent karyotypic rearrangements. Heng et al. confirm this conclusion: “when performing multiple runs of evolutionary experiments using cell populations derived from the same initial cells, the end results are not the same (individual cancer cells) and thus are not predictable.”¹²

In the following, we show a new example of karyotypic-phenotypic linkage, namely the evolution of a new, more dominant-neoplastic and immortal subclone from cen3telS2 PD84.

Near-tetraploid tumorigenic subclone overgrows near-diploid precursor cen3telS2 PD84. The speciation theory predicts that owing to the inherent flexibility of cancer karyotypes, cancers can evolve subspecies with enhanced tumorigenicity at high rates compared with mutation.⁴⁵,⁸⁰ As a possible example of subspeciation, we have analyzed here a tumorigenic variant of cen3telS2 PD84 that had supplanted this clone 59 generations after its first appearance, at PD143 (Mondello, unpublished). Compared with cen3telS2 PD84, the new neoplastic PD143 variant grew faster, and its cells looked more transformed, i.e., more amorphic and polymorphic than those of its precursor PD84 (not shown).
As a test for a karyotypic basis for this evolution, we compared the karyotype of PD143 to that of its suspected predecessor PD84. It is shown in Figure 7B that the karyotype of the new PD143 was different from, but possibly a polyploid version of, PD84. Following this clue we compared arrays of 20 karyotypes of cen3tel PD143 and PD84 side-by-side in Table 5 and Figure 8. These comparisons indicated that PD143 is a karyotypic duplication of PD84 on the following grounds: (1) PD143 has a clonal, near-tetraploid chromosome number of 85 ± 1, compared with the chromosome number of 46 ± 1 of PD84; (2) The copy numbers of 15 of the 23 intact chromosomes of PD143 are exact duplicates of the copy numbers of the same PD84-chromosomes. The remaining eight intact PD84-chromosomes were either not amplified or amplified 1.5- or 3-fold in PD143; (3) Both tumorigenic clones share one specific marker chromosome, der4. Further, the early presence of three near-tetraploids in the karyotype array of cen3tel PD84 (Fig. 8A) already indicated the proclivity of PD84 for tetraploidization, which eventually generated PD143.

We deduce: (1) from the high, 80–100% clonality of the chromosome copy numbers of cen3tel PD143, which is a proxy for stability (Table 5 and Fig. 8), and (2) from the immortality of its precursor that cen3tel PD143 has inherited karyotypic immortality from its precursor PD84.

Conclusions. (1) The duplication of the gene dosages of the cen3telS2 PD84 in the subspecies PD143 by polyploidization explains the enhanced tumorigenicity of cen3telS2 PD143 compared with PD84. It thus also explains its ability to supplant the whole PD84 culture within 20 to 40 generations (Figs. 8 and 11). Further the co-segregation of tumorigenicity and immortality over 59 unselected generations and during a major karyotypic remodeling lends new support to our theory that these characters are karyotypically linked.

(2) Since all six immortal and tumorigenic clones and subclones studied so far originated from cells transfected with overexpressed telomerase, it could be argued that clonal and flexible karyotypes were not sufficient to immortalize these clones, and hence also depend on telomerase for immortalization. In the next and last experiment we have addressed this question.

SV40 tumor virus induces immortal neoplastic clones with flexible karyotypes in cells of a telomerase-deficient mouse. To
determine whether either endogenous or exogenous telomerase is necessary for immortalization, we asked whether SV40 tumor virus generates immortal neoplastic clones in cells of a telomerase-deficient mouse. The study of Argilla et al. with telomerase-deficient mice, introduced above, already suggested that neoplastic transformation is telomerase-independent, but did not identify a mechanism of immortalization ("Introduction").

In view of this, we analyzed the karyotypes of foci of SV40-transformed lung and tail cells from a telomerase-deficient mouse for clonal and flexible, cancer-specific karyotypes. Such foci were obtained 2 to 3 mo after infection of primary cell cultures ("Materials and Methods"). Individual karyotypes of a lung cell focus, termed FL1 and of a tail cell focus, termed FT1, are shown in Figure 9, and arrays of 20 karyotypes are shown in Figure 10 and Table 6.

These data indicate that FL1 has a near triploid karyotype with clonal chromosome numbers of 59 ± 3 (compared with the 40 chromosomes a normal mouse). The copy numbers of 16 intact and four FL1-specific marker chromosomes were 65 to 100% clonal and thus stable during 35 and 65 cell generations (Fig. 10 and Table 6). The copy numbers of the remaining four intact chromosomes oscillated between two or three complementary percentages with high clonality (Table 6).

In agreement with the theory that cancer karyotypes are clonal but variable within clonal margins, the FL1 clone included minor fractions (0–35%) of chromosomes with near-clonal copy numbers that oscillated ± 1 around clonal values. In addition the clone had evolved five new, marker chromosomes at intermediate degrees of clonalities (25–55%) between generations PD35 to PD65 (Table 6).

Since the percentages of chromosomal clonalities and near-clonalities of the FL1 clone were stable for over 65 generations (except for some new subclonal marker chromosomes), we concluded that the FL1 clone is immortal based of the Hayflick definition. In the meantime, we have found that the clone was stable for another 25 generations, for a total of 90 generations in culture, but a new karyotype analysis has not been performed.

The tail-derived FT1 clone was hypo-diploid with a clonal chromosome number of 38 ± 1 (Figs. 9 and 10 and Table 6). The clonality of the chromosome copy numbers of FT1 at generation PD25 was very high, ranging between 94 and 100%. Thus FT1 was highly stable and is therefore likely to be immortal, although it has not yet been passaged and karyotyped for 50 generations.
We suggest that two factors explain the relatively high flexibility of FL1 compared with that of FT1: (1) the karyotype-destabilizing function of the high, near-triploid aneuploidy of FL1; and (2) probably the ongoing aneuploidyizing function of the SV40 T-antigen, knowing that the dosage and activity of the T-antigen of SV40-virus can be very high in some cells. Thus SV40 T-antigen and overexpressed telomerase play the same indirect role in immortalization and neoplastic transformation, namely the induction of random aneuploidy ("Results," "How does overexpressed telomerase induce..." and Fig. 4).

**Conclusions.** (1) Since both SV40-induced neoplastic clones of cells from a telomerase-deficient mouse were immortal and carried clonal and flexible karyotypes, and since the new clones and their new clonal karyotypes both appeared late after infection with SV40 virus, we conclude that these new clonal and flexible karyotypes were sufficient to transform and immortalize cells of telomerase-free mice.

(2) Further, we conclude that the role of the SV40-T-antigen in this immortalization experiment was to initiate the evolution of these new karyotypes by inducing random aneuploidy. Thus SV40 T-antigen and overexpressed telomerase play the same indirect role in immortalization and neoplastic transformation, namely the induction of random aneuploidy ("Results," "How does overexpressed telomerase induce..." and Fig. 4).

**Discussion**

Karyotypic theory of immortality.

With the longitudinal analyses of cells transfected with overexpressed telomerase or infected with SV40-virus, we have now before us a complete sequence of the karyotypic stages that generate cancer and immortality. Figure 11 diagrams these karyotypic stages during carcinogenesis of a virtual organ of $10^6$ cells: (1) the induction of random aneuploidy in an arbitrary 1% of normal cells by a carcinogen, such as overexpressed telomerase (Fig. 4) or SV40 virus T-antigen (Figs. 9 and 10); (2) self-catalyzed progression of random aneuploidy over many cell generations reaching up to 100% of the initiated cell population; the aneuploid human skin cells shown in Figure 4, 37 and 100 generations after transfection with overexpressed telomerase are examples; (3) the stochastic evolution of an autonomous cancer stem cell with a new, clonal flexible karyotype and phenotype; this new autonomous cancer cell supplants the $10^6$ non-cancerous precursors in our virtual organ of $10^6$ cells within 20 generations after its origin (Figs. 5 and 8); (4) self-catalyzed karyotypic variations of cancer cells generate new unselected subspecies, spontaneously (Fig. 5), and drug-resistant or metastatic subspecies, selectively.84,85

This sequence of events explains why in our experiments immortality and tumorigenicity: (1) correlated exactly with cancer-specific clonal and flexible karyotypes; (2) originated simultaneously with such karyotypes; and (3) progressed with subspecies of these karyotypes. Therefore, we conclude that

---

**Figure 7.** (A) Karyotype of the immortal tumorigenic clone cen3telS2 PD84, which arose from an independent preneoplastic aliquot of the cen3tel mass culture 84 generations after it was transfected with overexpressed telomerase. (See above Results, "How does overexpressed...") (B) Karyotype of cen3telS2 PD143, which supplanted the PD84 clone 59 generations after it was identified at PD84.
Table 5. Chromosome numbers and copy numbers of immortal, tumorigenic clones cen3telS2 PD84 and subclone cen3telS2 PD143

| Cen3telS2 clones       | PD84 | PD143 |
|-------------------------|------|-------|
| Chromosome no ± SD      | 46 ± 1 | 85 ± 1 |
| Metaphases (no.)        | 20   | 20    |
| Chromosomes             | Copy number (% clonal) |
| 1                       | 2(85) | 4(100) |
| 2                       | 2(75) | 4(90)  |
| 3                       | 2(85) | 4(95)  |
| 4                       | 1(80) | 2(100) |
| 5                       | 2(85) | 4(100) |
| 6                       | 2(85) | 4(95)  |
| 7                       | 2(85) | 6(90)  |
| 8                       | 2(80) | 2(80)  |
| 9                       | 2(85) | 4(85)  |
| 10                      | 1(90) | 3(95)  |
| 11                      | 2(75) | 4(95)  |
| 12                      | 2(85) | 4(100) |
| 13                      | 2(75) | 2(100) |
| 14                      | 2(75) | 3(95)  |
| 15                      | 1(85) | 3(100) |
| 16                      | 2(90) | 4(95)  |
| 17                      | 1(90) | 2(90)  |
| 18                      | 2(75) | 4(95)  |
| 19                      | 2(85) | 4(80)  |
| 20                      | 2(80) | 4(95)  |
| 21                      | 2(85) | 2(85)  |
| 22                      | 2(85) | 2(95)  |
| X                       | 2(80) | 3(95)  |
| Y                       | 0     | 0     |
| der(4)                  | 1(90) | 1(85)  |
| der(10;17)              | 1(85) | -     |
| der(15;7)               | 1(90) | -     |
| der(11;10)              | 1(5)  | -     |
| der(2;5)                | 1(5)  | -     |
| der(17;4)               | 1(5)  | -     |
| der(4;22)               | -     | 1(95)  |
| der(10)                 | -     | 1(100) |
| der(8;17)               | -     | 2(85)  |
| der(17)                 | -     | 2(85)  |
| der(19;17)              | -     | 1(5)   |
| der(7)                  | -     | 1(5)   |

Figure 8. Karyotype arrays of the immortal, tumorigenic clones cen3telS2 PD84 (A) and a sub-clone cen3telS2 PD143 (B) based on data of Table 5. The cen3telS2 PD84 clone arose spontaneously in an independently growing preneoplastic aliquot of the cen3tel mass culture (from which also cen3tel PD166 originated) 84 generations after transfection with overexpressed telomerase. Upon further cultivation for 59 generations, the cen3telS2 PD84 clone was supplanted by a more transformed and faster growing variant, cen3telS2 PD143. Comparative karyotype arrays revealed that PD143 is a near-tetraploid, clonal variant of cen3telS2 PD84 (Table 5).
clonal and flexible cancer karyotypes generate immortality and tumorigenicity simultaneously and independent of telomerase.

The literature supports this view on several grounds:

1. According to the “Mitelman Database of Chromosome Aberrations in Cancers,” an exact and huge correlation exists between immortality and individual, clonal yet flexible cancer karyotypes—namely over 61,000 cases. 

2. Levan and Biesele adduced independent evidence for the simultaneous origins of immortality and tumorigenicity in 1958: “One especially interesting change, demonstrated often to coincide with the establishment of the capacity for indeterminate growth in vitro, is the acquirement of malignant properties, made evident on inoculation of the cell strain in vivo.” Others have since described exact correlations between “indeterminate growth” in vitro and tumorigenicity.

3. Several previous studies observed that immortalization and neoplastic transformation are independent of telomerase-function: (a) Mondello et al. observed that the immortalization the cen3tel PD166 clone described above coincided with the loss, instead of an expected gain of telomere length. The telomeres of cen3tel PD166 were “decreased and stabilized around values lower than those observed in senescent cen3 cells (at) 6 kb” during immortalization. By contrast, the telomeres of mortal cen3 precursor cells measured 8.5 kb; (b) Another study found that the lengths of telomeres are reduced in 40% of all tumors compared with the normal tissue of origin; (c) Others wrote, in agreement with Holliday, that “Approximately a quarter of in vitro immortalized cell lines so far examined have no detectable telomerase activity, yet have very long and heterogeneous telomeres.”

In sum, the literature supports the theory that immortality is an integral part of the cancer karyotype, and is independent of telomerase.

**Why are cancers immortal?** Current cancer researchers and biology textbooks faithfully report that immortality is one of the “hallmarks of cancer.” There is, however, no compelling information on why cancers are immortal. According to cancer researcher Blagosklonny, immortality is in fact a “paradox,” because “it brings no immediate replicative advantage.”

The customary answer to the immortality question suggests that immortality is necessary for cancer cells to grow from single stem cells to the numbers of cells that generate fatal cancers. Since fatal cancers consist of 1 to 1,000 ml tissue or 10^9 to 10^12 cells, about 30 to 40 cell generations are necessary to generate such cancers from a single cancer stem cell (2^30 = 10^9 and 2^40 = 10^12).

![Figure 9](image-url)
Figure 10. Karyotype arrays of immortal, neoplastic clones of SV40 virus-transformed lung cells, FL1 (A and B) and tail cells, FT1 (C) from a telomerase-deficient mouse. The clones appeared 3 mo after infection by SV40 tumor virus together with their new clonal and flexible karyotypes. Karyotype arrays of the lung-derived focal culture, FL1 were determined 35 and 65 generations after isolation of the focal culture. The arrays show that the FL1 karyotype was near-triploid with near clonal FL1-specific chromosome numbers and chromosome copy numbers (see also Table 6). The karyotype array of the tail-derived focal culture, FT1 was determined 25 generations after isolation of the focal FT1 clone. The array shows that the FT1 karyotype was hypo-diploid with 94–100% clonal chromosome numbers and chromosome copy numbers.

But, according to the Hayflick limit the reproductive capacity of somatic cells is 50 generations, enough to generate $2^{50}$ or $10^{15}$ cells, the equivalent of 10 human bodies. As shown in this study and others cited above the reproductive capacity of human cells even from centenarians can actually be over 100 generations. There is also no consistent evidence that somatic cells must be “immortalized” by activated telomerase to produce sufficient numbers of cells for fatal cancers. For example, we found here that somatic cells of telomerase-deficient mice become immortal cancer cells without any telomerase. Moreover several studies have found normal telomere lengths in somatic human cells after a normal lifetime, even of 100 y. Such cells would also not depend on “immortalization” by activated telomerase to produce sufficient numbers of cells for carcinogenesis. So why are all cancers immortal, if immortality is not necessary to produce sufficient numbers of cells for fatal cancers?

Only the speciation theory of cancer offers a consistent explanation for the characteristic immortality of cancer cells: since cancers are indeed autonomous species of their own, they need a stable and, thus, immortal karyotype like all other species—the price “for crossing the threshold of autonomy,” as Huxley pointed out in 1956. The dynamic equilibrium between inherent karyotypic variation and selection for cancer-specific autonomy advanced here is a stable yet flexible mechanism that satisfies this requirement. The same mechanism would also explain how cancers escape Muller’s ratchet.

This view confirms and explains Blagosklonny’s proposal that immortality must be “a byproduct of something that brings about an immediate replicative advantage,” namely cancer-specific reproductive autonomy.

Flexibility of cancer karyotypes generating drug-resistance and metastasis at high rates. Immortality is just one of several consequences of the inherent karyotypic flexibility of cancer karyotypes. The karyotypic flexibility of cancers also explains the spontaneous karyotypic variations that generate subspecies that are
drug-resistant or metastatic—at rates of $10^{-4}$ to $10^{-5}$. These rates far exceed those of conventional gene mutations, which occur in cancer cells only at rates of $10^{-6}$ per dominant and $10^{-12}$ per recessive gene per mitosis. Thus the high, cancer-specific rates of phenotypic variations, to metastasis or drug-resistance, are consequences of inherently flexible cancer karyotypes, rather than of gene mutations.

The karyotypic variations that keep cancers immortal over thousands of cell generations also depend on these high rates of variation in order to exceed the rates of conventional lethal mutations of Muller's ratchet.

In sum, the inherent karyotypic flexibility of cancer is the basis for its existence, considering that it originates with an unstable karyotype, and it is the common cause of its most notorious, if gratuitous acquisitions: drug-resistance and metastasis. In the words of cancer researcher and physician Mark Vincent, “Thus is constructed a machine in which the associated DNA instability is not just a pointless collection of errors, but in fact the principal means to the goal of cellular survival.”

**Materials and Methods**

**Cells and cell culture.** The immortal, tumorigenic human cell lines, HA1, HA1–2 and BJ, prepared as described previously, were kindly provided by Robert Weinberg (Massachusetts Institute of Technology). Chiara Mondello (Istituto di Genetica Molecolare, University of Pavia) kindly provided the cen3tel cultures of primary skin cells at various generations after transfection with artificially overexpressed telomerase analyzed here. The primary cen3-cells had been derived from a human centenarian, as described previously. The cultures studied are labeled following the generations or population doublings (PD) after transfection of the primary culture with overexpressed telomerase, namely PD37, PD100, PD166, PD617, PD1014 and cen3telPD84 and PD143.

Primary lung and tail cultures were prepared from a young telomerase-minus mouse, strain B6.Cg-Terc, from the Jackson Laboratory. For this purpose the lung and tail of the mouse were excised shortly after it was killed with CO2. The tissues were then minced with razor blades, washed free of blood cells and debris and then incubated in serum-free medium containing about 0.5% trypsin at 37°C on a shaker for 15 to 30 min. We monitored the dissociation of tissue nuggets into single cells by checking aliquots of the trypsin-digest under the microscope.

Cells were then incubated in culture medium RPM1640 supplemented with 0.1–0.5 mg/ml collagenase (Sigma) to dissociate trypsin resistant cell nuggets for several up to 24 h, depending on the degree of dissociation. SV40 was kindly provided by Michele Carbone (Cancer Research Center of Hawaii, University of Hawaii) or purchased from the American Type Culture Collection. The mouse cell cultures were then infected with SV40 virus and incubated 2–3 mo until foci of transformed cells were observed, as described previously.

| Table 6. Chromosome numbers and copy numbers of two immortal SV40-transformed clones of telomerase-deficient mouse cells, FL1 and FT1 |
|---------------------------------|----------------|----------------|----------------|
| Neoplastic clones              | FT1 PD25       | FL1 PD35       | FL1 PD65       |
| Chromosome no. ± SD            | 38 ± 1         | 61 ± 3         | 59 ± 3         |
| Metaphases (no.)               | 16             | 20             | 20             |
| Chromosomes                    |                |                |                |
| 1                              | 2(100)         | 3(100)         | 3(80)          |
| 2                              | 2(100)         | 3(85)          | 3(95)          |
| 3                              | 2(100)         | 2(75)          | 3(85)          |
| 4                              | 2(100)         | 1(95)          | 1(95)          |
| 5                              | 2(100)         | 4(85)          | 2(35), 3(40), 4(20) |
| 6                              | 2(100)         | 2(60), 3(30)   | 1(55), 2(45)   |
| 7                              | 2(100)         | 3(70)          | 3(95)          |
| 8                              | 2(100)         | 3(35), 4(50)   | 3(50), 4(40)   |
| 9                              | 2(100)         | 3(70)          | 3(85)          |
| 10                             | 2(94)          | 3(35), 4(60)   | 4(80)          |
| 11                             | 2(100)         | 4(85)          | 4(60)          |
| 12                             | 1(100)         | 2(95)          | 2(85)          |
| 13                             | 2(94)          | 2(100)         | 2(90)          |
| 14                             | 1(100)         | 4(85)          | 2(80)          |
| 15                             | 2(94)          | 3(65)          | 3(30), 4(45)   |
| 16                             | 2(100)         | 3(85)          | 2(80)          |
| 17                             | 2(100)         | 3(80)          | 1(65)          |
| 18                             | 2(100)         | 3(75)          | 2(70)          |
| 19                             | 2(100)         | 3(35), 4(55)   | 3(45), 4(15)   |
| X                              | 1(100)         | 2(100)         | 2(70)          |
| Y                              | 1(69), 2(31)   | 0              | 0              |
| der(4) long                    | -              | 1(95)          | 1(85)          |
| der(4;12)                      | -              | 1(90)          | 1(95)          |
| der(6;3;19)                    | -              | 1(65)          | 1(70)          |
| der(13;15)                     | -              | 1(100)         | 1(75)          |
| i(17)                          | -              | -              | 1(55)          |
| der(16;19)                     | -              | -              | 1(55)          |
| i(6)                           | -              | -              | 1(35)          |
| der(18;19)                     | -              | -              | 1(35)          |
| der(5;14)                      | -              | -              | 1(25)          |
Figure 11. Karyotypic stages during carcinogenesis of a virtual organ of $10^6$ cells: (1) The induction of random aneuploidy in an arbitrary 1% of normal cells by a carcinogen, such as overexpressed telomerase (Fig. 4) or SV40 virus (Figs. 9 and 10); (2) Self-catalyzed progression of aneuploidy over many cell generations up to 100% of the initiated cell population, as for example in the human skin cells 100 generations after aneuploidization by overexpressed telomerase shown in Figure 4; (3) The stochastic evolution of an autonomous cancer stem cell with a new, clonal flexible karyotype and phenotype. The new autonomous cancer cell supplants the $10^6$ non-cancerous precursors in our Petri dish within 20 generations after its origin (Figs. 5 and 8); (4) Self-catalyzed karyotypic variations of cancer cells generate new unselected subspecies, spontaneously (Figs. 5 and 8) and drug-resistant or metastatic subspecies, selectively (see text).

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
We specifically thank Chiara Mondello (Istituto di Genetica Molecolare, University of Pavia) for providing the cen3tel system of human skin fibroblasts to study immortalization and for her reliable and generous advice. Further, we thank Douglas Brash (Yale Comprehensive Cancer Center, Yale School of Medicine), Josh Nicholson (Department of Biological Sciences, Virginia Tech) and Rainer Sachs (Dept. Mathematics and Physics, UC Berkeley) for critical reviews and helpful comments on the manuscript. In addition we gratefully acknowledge Alfred Boecking (Universitätsklinikum Duesseldorf), Michele Carbone (Cancer Research Center of Hawaii, University of Hawaii), Alice Fabarius (University of Heidelberg at Mannheim), Richard Harland (Department Molecular and Cell Biology, UC Berkeley), Ruediger Hehlmann (University of Heidelberg at Mannheim), Daniele Mandrioli (Cesare Maltoni Cancer Research Center, Ramazzini Institute), David Rasnick (former visiting scholar at UC Berkeley) and Peter Walian (Lawrence Berkeley National Laboratory, Donner Lab) for valuable information, many timely alerts and critical discussions. Finally we thank our three summer interns of 2012, Elisabeth Berger (Berkeley and Brown University), Gregory Hui and Max Duesberg for catalyzing this project by their lively discussions and ideas. Bong-Gyoon Han is specifically thanked for drafting and shaping Figure 11 (Lawrence Berkeley National Laboratory, Donner Lab). Our research would not have been possible without the generous support from the philanthropists Dr Christian Fiala, Rajeev and Christine Joshi, Robert Leppo, Peter Rozsa of the Taubert Memorial Foundation, Howard Urnovitz (Chronix Biomedical), a Foundation that prefers to remain anonymous and other private sources.
85. Duesberg P, Li R, Sachs R, Fabarius A, Upender MB, Hehlmann R. Cancer drug resistance: the central role of the karyotype. Drug Resist Update 2007; 10:51-8; PMID:17387035; http://dx.doi.org/10.1016/j.drup.2007.02.002

86. Mielke F, Johansson B, Mertens F, Mitelman Database of Chromosome Aberrations in Cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman. NIH, 2012

87. McElrime RM, Cornell LL. Tumorigenicity of tissue culture cells. Cancer Res 1959; 19:1040-4

88. Schmitt H, Blin N, Zanhk H, Scherhan H. Telomere length variation in normal and malignant human tissues. Genes Chromosomes Cancer 1994; 11:171-7; PMID:7530486; http://dx.doi.org/10.1002/gcc.2870110360

89. Holliday R. Endless quest. Bioscience 1996; 18:3-5; PMID:8593161; http://dx.doi.org/10.1002/bies.950180103

90. Bryan TM, Reddel RR. Telomere dynamics and telomerase activity in vitro immortalised human cells. Eur J Cancer 1997; 33:767-73; PMID:9282115; http://dx.doi.org/10.1016/S0959-8049(97)00065-8

91. Pinot HC. Fundamentals of Oncology. New York: Marcel Dekker, Inc., 2002

92. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25:585-621; PMID:13995658; http://dx.doi.org/10.1016/0014-4827(61)90192-6

93. Zhai G, Avir A, Hunter DJ, Hart DJ, Gardner JP, Kimura M et al. Reduction of leucocyte telomere length in radiographic hand osteoarthropathies: a population-based study. Ann Rheum Dis 2006; 65:144-8; PMID:17038452; http://dx.doi.org/10.1136/ard.2005.050903

94. MacIntyre A, Brouilette SW, Lamb K, Radakrishnan K, McGlynn L, Chee MM, et al. Association of increased telomere lengths in limited scleroderma, with a lack of age-related telomere erosion. Ann Rheum Dis 2008; 67:1780-2; PMID:18662931; http://dx.doi.org/10.1136/ard.2006.050903

95. Xing J, Aijan JA, Chen M, Izzo J, Lin J, Chen Z, et al. Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer. Cancer Prev Res (Phila) 2009; 2:465-9; PMID:19401529; http://dx.doi.org/10.1158/1940-6207.CAPR-08-0227

96. Chiang YJ, Calado RT, Hatzcock KS, Lansdorp PM, Young NS, Hodes RJ. Telomere length is inherited with recombination in healthy human diploid cells. Nat Genet 2000; 25:218-22; PMID:10728168; http://dx.doi.org/10.1038/77105

97. Duesberg P, Stindl R, Hehlmann R. Cancer drug resistance: the central role of the karyotype. Drug Resist Update 2007; 10:51-8; PMID:17387035; http://dx.doi.org/10.1016/j.drup.2007.02.002

98. Duesberg P, Li R, Sachs R, Fabarius A, Upender MB, Hehlmann R. Cancer drug resistance: the central role of the karyotype. Drug Resist Update 2007; 10:51-8; PMID:17387035; http://dx.doi.org/10.1016/j.drup.2007.02.002

99. Duesberg P, Stindl R, Hehlmann R. Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome rearrangements that are catalyzed by aneuploidy. Proc Natl Acad Sci USA 2000; 97:14295-300; PMID:11121035; http://dx.doi.org/10.1073/pnas.97.26.14295

100. Duesberg P, Stindl R, Hehlmann R. Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome rearrangements catalyzed by aneuploidy. Proc Natl Acad Sci USA 2001; 98:11283-8; PMID:11553793; http://dx.doi.org/10.1073/pnas.10199898